

## Special Issue

# Immunological Responses to mRNA Vaccines

### Message from the Guest Editor

Vaccines provide immunity by inducing immunogenicity through vaccination. They reduce the risk of disease for individuals and decrease the likelihood of epidemic outbreaks. Research on vaccine immunogenicity is vital for determining vaccination strategies such as the number of doses, dosing intervals and target populations. This issue aims to explore how host immunity is induced, enhanced and maintained against microorganisms through vaccination. As vaccine development becomes increasingly advanced, immunity against infectious disease is achieved primarily through vaccine-induced immunity instead of natural infection. As a result, studies on the duration of vaccine-induced immunogenicity are becoming more important. Additionally, quantifying immunogenicity helps differentiate between populations with low and high immune responses. Given the rising number of immunocompromised individuals, research targeting special populations is urgently needed. We welcome original research articles and reviews on topics that may include immunogenicity assessments using various methodologies, as well as large-scale studies evaluating immune responses following vaccination.

---

### Guest Editor

Dr. Hyeri Seok

Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan-si 15355, Republic of Korea

---

### Deadline for manuscript submissions

closed (30 April 2026)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/251773](https://mdpi.com/si/251773)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).